<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, April 17, 2018 (HealthDay News) — Males with BRCA<\/i> mutations have increased incidence of malignant disease, specifically prostate, melanoma, pancreas, and breast cancers, according to a research letter published online April 12 in JAMA Oncology<\/i>.<\/p>\n
Roy Mano, M.D., from Rabin Medical Center in Petach Tikva, Israel, and colleagues evaluated 196 male BRCA<\/i> carriers (117 BRCA1<\/i> and 79 BRCA2<\/i>) between February 2014 and February 2017. Using a predefined protocol, patients aged 40 years or older were screened for prostate, breast, colorectal, pancreatic, and skin malignant abnormalities.<\/p>\n
The researchers found that 17 percent of the patients were diagnosed with 46 malignant abnormalities; 28 percent were identified during screening. At first cancer diagnosis, the median age was 54 years. Multiple malignant abnormalities were reported in seven patients, with a median of three per patient. Prostatic adenocarcinoma was the most common malignant abnormality (8.6 and 3.8 percent of BRCA1<\/i> and BRCA2<\/i> carriers, respectively). Men with BRCA<\/i> mutations had a significant increase in the overall incidence of malignant disease compared with the Jewish-Israeli male population (standardized incidence ratio, 8). Elevated incidence of prostate, melanoma, pancreas, and breast cancers, but not colon cancer, was seen in association with BRCA<\/i> mutations.<\/p>\n
“Our initial findings suggest that in addition to screening for prostate and breast cancer, as recommended in current guidelines, there may be a role for screening for pancreatic cancer and melanoma, whereas screening for colon cancer may not be justified,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n